AVBP ArriVent BioPharma Inc.
Price (delayed)
$21.88
Market cap
$744.27M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.56
Enterprise value
$670.16M
We are a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. We seek to utilize
Highlights
The EPS has soared by 92% YoY and by 73% from the previous quarter
AVBP's debt is down by 44% year-on-year and by 17% since the previous quarter
ArriVent BioPharma's quick ratio has decreased by 32% QoQ and by 2.1% YoY
The net income has declined by 16% year-on-year
Key stats
What are the main financial stats of AVBP
Market
Valuations
Earnings
Shares outstanding
34.02M
Market cap
$744.27M
Enterprise value
$670.16M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.86
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$94.31M
Net income
-$80.49M
EBIT
-$80.49M
EBITDA
-$80.49M
Free cash flow
-$70.21M
Per share
Balance sheet
Liquidity
EPS
-$2.56
EPS diluted
-$2.56
Free cash flow per share
-$2.23
Book value per share
$7.65
Revenue per share
$0
TBVPS
$8.74
Total assets
$274.94M
Total liabilities
$17.29M
Debt
$176,000
Equity
$257.65M
Working capital
$209.71M
Debt to equity
0
Current ratio
13.14
Quick ratio
12.67
Net debt/EBITDA
0.92
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-26.7%
Return on equity
-28%
Return on invested capital
-181.3%
Return on capital employed
-31.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AVBP stock price
How has the ArriVent BioPharma stock price performed over time
Intraday
-2.54%
1 week
0.32%
1 month
-18.51%
1 year
10.78%
YTD
-17.87%
QTD
-17.87%
Financial performance
How have ArriVent BioPharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$94.31M
Net income
-$80.49M
Gross margin
N/A
Net margin
N/A
ArriVent BioPharma's operating income has decreased by 26% YoY
The net income has declined by 16% year-on-year
Growth
What is ArriVent BioPharma's growth rate over time
Valuation
What is ArriVent BioPharma stock price valuation
P/E
N/A
P/B
2.86
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 92% YoY and by 73% from the previous quarter
AVBP's P/B is 18% above its last 4 quarters average of 2.5
The equity has contracted by 7% from the previous quarter
Efficiency
How efficient is ArriVent BioPharma business performance
ArriVent BioPharma's ROIC has soared by 83% YoY
ArriVent BioPharma's ROE has increased by 36% from the previous quarter
ArriVent BioPharma's ROA has increased by 33% YoY and by 10% from the previous quarter
Dividends
What is AVBP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AVBP.
Financial health
How did ArriVent BioPharma financials performed over time
ArriVent BioPharma's total assets has soared by 69% YoY but it has decreased by 6% from the previous quarter
The company's total liabilities rose by 46% YoY and by 14% QoQ
AVBP's debt is 100% smaller than its equity
AVBP's debt is down by 44% year-on-year and by 17% since the previous quarter
The equity has contracted by 7% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.